Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.

Abstract

COVID-19 has become a global concern. A large number of reports have explained the clinical characteristics and treatment strategies of COVID-19, but the characteristics and treatment of COVID-19 patient with systemic lupus erythematosus (SLE) are still unclear. Here, we report the clinical features and treatment of the first SLE patient with confirmed COVID-19 pneumonia. This was a 39-year-old woman, diagnosed with SLE 15 years ago, whose overall clinical characteristics (symptoms, laboratory tests, and chest CTs) were similar to those of the general COVID-19 patients. She continued to take the previous SLE drugs (doses of glucocorticoids, hydroxychloroquine, and immunosuppressive agents were not reduced) and was treated with strict antiviral and infection prevention treatment. After the first discharge, she got a recurrence of COVID-19 during her home isolation, and then returned to hospital and continued the previous therapy. Finally, this long-term immune suppressive patient's COVID-19 was successfully cured. The successful recovery of this case has significant reference value for the future treatment of COVID-19 patients with SLE. Key Points • COVID-19 patients with SLE is advocated to continue the medical treatment for SLE. • Hydroxychloroquine may have potential benefits for COVID-19 patients with SLE. • COVID-19 patients with SLE is prone to relapse, and multiple follow-ups are necessary.

• Authors: Feng He, Qingqing Luo, Ming Lei, Lixin Fan, Xinning Shao, Kaiyuan Hu, Shuguang Qin, Na Yu, Jie Cao, Liuping Yang
• Journal: Clinical rheumatology (Clin Rheumatol) Vol. 39 Issue 9 Pg. 2803-2810 (Sep 2020) ISSN: 1434-9949 [Electronic] Germany
• PMID: 32725351 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Antirheumatic Agents
• Antiviral Agents
• Drug Combinations
• Glucocorticoids
• Immunosuppressive Agents
• RNA, Viral
• lopinavir-ritonavir drug combination
• Lopinavir
• Hydroxychloroquine
• Mycophenolic Acid
• Ritonavir
• Moxifloxacin
• Prednisone

Topics

• Adult
• Anti-Bacterial Agents (therapeutic use)
• Antirheumatic Agents (therapeutic use)
• Antiviral Agents (therapeutic use)
• Betacoronavirus
• COVID-19
• COVID-19 Testing
• Clinical Laboratory Techniques
• Coronavirus Infections (complications, diagnosis, drug therapy)
• Drug Combinations
• Female
• Glucocorticoids (therapeutic use)
• Humans
• Hydroxychloroquine (therapeutic use)
• Immunosuppressive Agents (therapeutic use)
• Lopinavir (therapeutic use)
• Lung (diagnostic imaging)
• Lupus Erythematosus, Systemic (complications, drug therapy)
• Moxifloxacin (therapeutic use)
• Mycophenolic Acid (therapeutic use)
• Pandemics
• Pneumonia, Viral (complications, diagnosis, drug therapy)
• Prednisone (therapeutic use)
• RNA, Viral
• Recurrence
• Reverse Transcriptase Polymerase Chain Reaction
• Ritonavir (therapeutic use)
• SARS-CoV-2
• Tomography, X-Ray Computed